Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics (NASDAQ:PTGX) and Viatris (NASDAQ:VTRS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.

Which has more risk & volatility, PTGX or VTRS?

Protagonist Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Is PTGX or VTRS more profitable?

Protagonist Therapeutics has a net margin of 52.76% compared to Viatris' net margin of -5.87%. Protagonist Therapeutics' return on equity of 34.68% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	52.76%	34.68%	30.98%
Viatris	-5.87%	16.46%	7.09%

Do institutionals and insiders hold more shares of PTGX or VTRS?

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 4.9% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor PTGX or VTRS?

Protagonist Therapeutics received 269 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 61.73% of users gave Protagonist Therapeutics an outperform vote while only 34.85% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Protagonist Therapeutics	Outperform Votes 292 61.73%	Underperform Votes 181 38.27%
Viatris	Outperform Votes 23 34.85%	Underperform Votes 43 65.15%

Which has preferable earnings and valuation, PTGX or VTRS?

Viatris has higher revenue and earnings than Protagonist Therapeutics. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$207.80M	13.69	-$78.96M	$0.75	61.21
Viatris	$14.33B	0.70	$54.70M	-$3.17	-2.68

Does the media prefer PTGX or VTRS?

In the previous week, Viatris had 20 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 30 mentions for Viatris and 10 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.18 beat Viatris' score of -0.02 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	2 Positive mention(s)	25 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts prefer PTGX or VTRS?

Protagonist Therapeutics presently has a consensus price target of $65.44, suggesting a potential upside of 42.55%. Viatris has a consensus price target of $10.50, suggesting a potential upside of 23.53%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Viatris	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Protagonist Therapeutics beats Viatris on 16 of the 19 factors compared between the two stocks.